Sen, Shiraj
Kato, Shumei
Agarwal, Rishi
Piha-Paul, Sarina
Hess, Kenneth
Karp, Daniel
Janku, Filip
Fu, Siqing
Naing, Aung
Pant, Shubham
Falchook, Gerald
Tang, Chad
Wu, Xifeng
Ye, Yuanqing
Tsimberidou, Apostolia
Subbiah, Vivek
Kurzrock, Razelle
Byers, Lauren
Westin, Shannon
Lim, JoAnn
Bean, Stacie
Bass, Allison
Nguyen, Ly
Meric-Bernstam, Funda
Hong, David
Article History
Received: 30 November 2017
Revised: 6 March 2018
Accepted: 8 March 2018
First Online: 26 April 2018
Competing interests
: This was an investigator initiated trial. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. David Hong was the principal investigator of this trial and receives research grant funding from Bayer, Lily, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichi-Sanko, Eisai and has a consulting or advisory role at Bayer, Baxter, and Guidepoint Global and ownership interests in OncoResponse. Other authors report no competing interests.
: This study (NCT01113476) was performed at The University of Texas MD Anderson Cancer Center under a protocol approved by MD Anderson’s Institutional Review Board (protocol number 2009–0855). The participants gave informed written consent.
: All authors provided consent for publication.
: All data supporting the results reported in the article were obtained with permission from the MD Anderson’s Institutional Review Board and are stored in the Investigational Cancer Therapeutics department.